Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis's Midostaurin To Fill 30 Year Void In AML Treatment

This article was originally published in Scrip

Executive Summary

First Phase III data for Novartis AG's acute myeloid leukemia (AML) therapy midostaurin has hematologists excited as the drug "inches forward" towards a market approval – opening up the door for possible evolution of standard of care for AML patients, which has been sealed shut for the past 30 years.

You may also be interested in...



Cyclacel CEO Explains How Sapacitabine Might Get Cleared For AML, Despite Phase III Failure

The company will talk to regulators in the US and Europe to see if the drug could be considered in elderly patients with low baseline peripheral white blood cells, who fared better than others in the failed SEAMLESS study.

Femtech Presents Enticing Market Opportunity

A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.

Execs On The Move, Sep 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Topics

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel